Atrasentan
Brand names: Vanrafia · Active ingredient: Atrasentan Hydrochloride
In short: VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. This indication is approved under accelerated approval based on a reduction of proteinuria .
What is Atrasentan used for?
VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.
This indication is approved under accelerated approval based on a reduction of proteinuria . It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
⚠ Boxed warning (FDA's strongest warning)
VANRAFIA is contraindicated for use in pregnant patients; it may cause major birth defects based on animal data [see Contraindications (4.1), Warnings and Precautions (5.1), Use in Specific Populations (8.1)]. Exclude pregnancy prior to initiation of treatment with VANRAFIA. Advise use of effective contraception before the initiation of treatment, during treatment, and for two weeks after discontinuation of treatment with VANRAFIA. Stop VANRAFIA as soon as possible if the patient becomes pregnant [see Dosage and Administration (2.1), Contraindications (4.1), Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)].
Atrasentan dosage
Exclude pregnancy before initiating VANRAFIA .
The recommended dose of VANRAFIA is 0.75 mg administered orally once daily with or without food .
Swallow tablets whole. Do not cut, crush, or chew.
If a dose or doses are missed, take the prescribed dose at the next scheduled time. Do not double the dose to make up for a missed dose.
How to take Atrasentan — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide)
Embryo-Fetal Toxicity
Educate and counsel female patients of reproductive potential to use effective contraception prior to starting treatment with VANRAFIA, during treatment and for two weeks after treatment discontinuation. Patients who can become pregnant should have a negative pregnancy test prior to treatment with VANRAFIA [see Dosage and Administration (2.1), Contraindications (4.1), Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)].
Patients should be instructed to immediately contact their physician if they suspect they may be pregnant. Patients should seek additional contraceptive advice as needed.
Educate and counsel patients who can become pregnant on the use of emergency contraception in the event of unprotected sex or contraceptive failure.
Advise patients to contact their healthcare provider if they want to change the form of birth control which is used to ensure that another acceptable form of birth control is selected.
Hepatotoxicity
Some members of this pharmacological class are hepatotoxic. Educate patients on signs of hepatotoxicity. …
Warnings & precautions
Do not take this medicine if: Use of VANRAFIA is contraindicated in patients who are pregnant [see Dosage and Administration (2.1), Warnings and Precautions (5.1), Use in Specific Populations (8.1)].
VANRAFIA is contraindicated in patients with a history of a hypersensitivity reaction to atrasentan or any component of the product.
Based on data from animal reproduction studies, VANRAFIA may cause fetal harm when administered to a pregnant patient and is contraindicated during pregnancy. The available human data for endothelin receptor antagonists do not establish the presence or absence of major birth defects related to the use of VANRAFIA. Counsel patients who can become pregnant of the potential risk to a fetus. Exclude pregnancy prior to initiation of treatment with VANRAFIA. Advise patients to use effective contraception prior to initiation of treatment, during treatment, and for two weeks after discontinuation of treatment with VANRAFIA . When pregnancy is detected, discontinue VANRAFIA as soon as possible [see Dosage and Administration (2.1), Contraindications (4.1), Use in Specific Populations (8.1, 8.3)].
Some endothelin receptor antagonists (ERAs) have caused elevations of aminotransferases, hepatotoxicity, and liver failure. Asymptomatic and transient transaminase elevations have been observed with VANRAFIA . Obtain liver enzyme testing before initiating VANRAFIA and repeat during treatment as clinically indicated. In patients with elevated aminotransferases at baseline (>3 × upper limit of normal [ULN]), consider periodic liver test monitoring. Do not initiate VANRAFIA in patients with severe hepatic impairment.
Advise patients to report symptoms suggesting hepatic injury (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching). …
Atrasentan side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Embryo-fetal Toxicity
Hepatotoxicity
Fluid Retention
Decreased Sperm Counts
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of VANRAFIA was evaluated in ALIGN (NCT04573478), a randomized, double-blind, placebo controlled clinical study in 403 adults with IgAN . The median duration of treatment was 47 weeks (range: 0 to 128 weeks). The most common adverse reactions (≥ 5%) with VANRAFIA were peripheral edema and anemia. Table 1 describes the adverse reactions that occurred in ≥ 2% of patients treated with VANRAFIA and higher than placebo in the ALIGN study.
*Includes related terms
**Elevations in ALT or AST > 3-fold upper limit of normal (ULN)
Adverse Reaction | VANRAFIA(N = 201)n (%) | Placebo(N = 202)n (%)
Peripheral edema* | 21 (10%) | 14 (7%)
Anemia* | 12 (6%) | 2 (1%)
Liver transaminase elevation** | 4 (2%) | 2 (1%)
Laboratory Tests and Vital Signs
Hemoglobin Decrease
At Week 36, the mean change in hemoglobin from baseline for those patients receiving VANRAFIA in the ALIGN study was -0.7 g/dL compared to -0.2 g/dL for those receiving placebo. …
Drug interactions
Strong or Moderate CYP3A Inducers
Avoid concomitant use with a strong or moderate CYP3A inducer.
Atrasentan is a CYP3A substrate . Concomitant use with a strong and moderate CYP3A inducer is expected to decrease atrasentan exposure , which may reduce VANRAFIA efficacy.
OATP1B1/1B3 Inhibitors
Avoid concomitant use with organic anion transporting polypeptides 1B1/1B3 (OATP1B1/1B3) inhibitors.
Atrasentan is a OATP1B1/1B3 substrate . Concomitant use with a OATP1B1/1B3 inhibitor increases atrasentan exposure , which may increase the risk of VANRAFIA adverse reactions.
About this medicine
VANRAFIA contains atrasentan, an endothelin type A (ETA) receptor antagonist. The chemical name of atrasentan hydrochloride is (2R, 3R, 4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid hydrochloride. Atrasentan hydrochloride has a molecular weight of 547.09 g/mol, a molecular formula of C29H38N2O6HCl and the following structural formula.
Atrasentan is a slightly hygroscopic white to off-white powder that is slightly soluble in water.
VANRAFIA is available as a film-coated tablet for oral administration. Each VANRAFIA tablet contains 0.75 mg atrasentan (equivalent to 0.803 mg of atrasentan hydrochloride) and contains the following excipients: crospovidone, glyceryl dibehenate, hypromellose, lactose monohydrate, L-cysteine hydrochloride monohydrate, polyethylene glycol, and silicon dioxide.
How it works: Atrasentan is an ETA receptor antagonist (Ki = 0.034 nM) with >1800-fold selectivity for the ETA receptor compared to the endothelin type B receptor (Ki = 63.3 nM). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9a7e7f85-bfd0-44a0-beda-3bcfa8215c64. Read the full official label on DailyMed.